Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Emons

Showing results (131-140 of 137) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 137 results.
Annals of Surgical Oncology|February 20, 2009
Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosisP Harter, M Hahmann, H J Lueck, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2004
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trialM Untch, H Eidtmann, A du Bois, et al.
Zentralblatt Fur Gynakologie|February 2, 2006
[Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO]B Schmalfeldt, A du Bois, A Burges, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 18, 2015
The effect of EUSOMA certification on quality of breast cancer careP A van Dam, M Tomatis, L Marotti, et al.
Geburtshilfe Und Frauenheilkunde|April 29, 2014
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013U Wagner, P Harter, F Hilpert, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2017
Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centresP A van Dam, M Tomatis, L Marotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 14

Showing results (131-140 of 137) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 137 results.
Annals of Surgical Oncology|February 20, 2009
Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosisP Harter, M Hahmann, H J Lueck, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2004
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trialM Untch, H Eidtmann, A du Bois, et al.
Zentralblatt Fur Gynakologie|February 2, 2006
[Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO]B Schmalfeldt, A du Bois, A Burges, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 18, 2015
The effect of EUSOMA certification on quality of breast cancer careP A van Dam, M Tomatis, L Marotti, et al.
Geburtshilfe Und Frauenheilkunde|April 29, 2014
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013U Wagner, P Harter, F Hilpert, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2017
Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centresP A van Dam, M Tomatis, L Marotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 14